A randomized trial using in situ viral imaging and mass spectrometry reported that first-line dolutegravir/lamivudine therapy reaches HIV-1 infected cells within lymph node tissue and coincides with a rapid decline of infected cells. The work used reservoir-relevant measurements rather than relying solely on blood viral load. The trial supports the pharmacologic plausibility of current first-line regimens achieving early suppression in tissue compartments, where viral persistence drives long-term disease management. It also demonstrates the growing role of advanced reservoir imaging and proteomic/biochemical quantification. While duration of suppression and relapse dynamics are not described in the provided headline text, the data provide a validation step for clinicians and payers monitoring “where HIV is hiding,” not just whether plasma levels remain undetectable.